Alaunos Therapeutics, Inc. (TCRT) filings document an early-stage biotechnology issuer with a developing small-molecule program, a legacy TCR-T oncology platform and a public-company capital structure. Form 8-K reports cover ALN1003 preclinical disclosures, material agreements, settlement matters, Nasdaq continued-listing notices, governance changes, director and officer transitions, and modifications to stockholder rights.
Registration statements, annual meeting reports and periodic-report references describe securities offerings, authorized common stock, stockholder voting results, operating and financial results, risk factors, and stockholders' equity used in Nasdaq compliance determinations.
Alaunos Therapeutics, Inc. director Michael Allen Jerman acquired 20,990 shares of common stock on October 6, 2026; the shares were issued in lieu of board fees. The reported per-share amount was $0.7444, and direct holdings following the award were 44,749 shares.
Alaunos Therapeutics, Inc. (TCRT) entered into definitive agreements for a registered direct offering of 380,469 shares of common stock and 386,654 Pre-Funded Warrants to purchase common stock. The shares are priced at $1.46 each and the Pre-Funded Warrants at $1.459 each under an effective Form S-3 shelf registration.
The transaction closed on September 21, 2026 and generated approximately $1,120,000 in gross proceeds and about $915,400.50 in net proceeds after fees and expenses. Alaunos plans to use the net proceeds for general corporate purposes, including working capital. The Pre-Funded Warrants are exercisable immediately at $0.001 per share, have no expiration, and include a beneficial ownership limitation of 4.99% (or 9.99% if elected, with 60 days’ notice). Dawson James Securities, Inc. acted as exclusive placement agent and received an 8% cash fee on gross proceeds, and company officers and directors agreed to a 15-day lock-up on additional equity sales, subject to exceptions.
Alaunos Therapeutics, Inc. (TCRT) is conducting a primary offering of 380,469 shares of common stock at $1.46 per share and 386,654 pre-funded warrants at $1.459 each, for aggregate gross proceeds of up to $1,120,000.54 on a best-efforts basis under its $50 million shelf.
The pre-funded warrants are immediately exercisable at $0.001 per share and remain outstanding until fully exercised; assuming full exercise, shares outstanding would rise from 2,546,666 to 3,313,789. Estimated net proceeds of about $915,400, after 8% placement fees and expenses, are earmarked for working capital and general corporate purposes.
Alaunos is a preclinical-stage company focused on oral small-molecule obesity drugs and reported a $4.2 million net loss for 2025, with an accumulated deficit of $924.6 million. Its auditors included a going-concern explanatory paragraph, and the company has a Nasdaq stockholders’ equity deficiency notice and a disclosed material weakness in internal controls.
Alaunos Therapeutics, Inc. (TCRT) reported that on September 16, 2026 its Board of Directors approved and adopted Second Amended and Restated By-Laws, effective immediately, fully replacing the by-laws adopted January 8, 2026.
The principal change revises the stockholder meeting quorum requirement in Article 2, Section 2.8. Previously, a quorum required the presence in person or by proxy of the holders of a majority in voting power of all outstanding shares entitled to vote. Under the new by-laws, a quorum is reached when holders of one-third (1/3) in voting power of outstanding shares entitled to vote are present in person or by proxy. Provisions governing adjournment without a quorum are otherwise unchanged, the quorum requirement for Board and committee meetings remains a majority, and other modifications are described as conforming, clarifying, and non-substantive. The full text of the Second Amended and Restated By-Laws is included as Exhibit 3.1.
Alaunos Therapeutics, Inc. reports that it remains a preclinical-stage obesity and metabolic disorders company with no product revenue and continued losses. For the six months ended June 30, 2026, it recorded a net loss of $1.96 million and had an accumulated deficit of $926.6 million since inception. Cash and cash equivalents were only $0.12 million, with total assets of $1.52 million and stockholders’ equity of $0.65 million, resulting in a working capital deficit.
Management states that current capital will fund operations only into the third quarter of 2026 and concludes there is substantial doubt about the company’s ability to continue as a going concern without substantial additional financing. The company has an equity purchase agreement that yielded just $70,000 of net proceeds in the first half of 2026 and has no committed additional capital. Alaunos also received a Nasdaq stockholders’ equity deficiency notice, as equity is below the $2.5 million continued listing requirement, and it highlights possible future exposure to a proposed $5.0 million Market Value of Listed Securities standard.
Operationally, Alaunos is winding down legacy TCR-T programs and focusing on lead small-molecule candidate ALN1003 for obesity and metabolic syndrome, reporting encouraging non-GLP diet-induced obesity mouse data across weight loss, liver markers, and insulin-resistance-related biomarkers. However, these findings are preclinical, non-GLP, and subject to substantial development and financing risks before any clinical testing.
Alaunos Therapeutics, Inc. reported that CEO Holger Weis received a grant of common stock as part of his compensation. On 2026-08-06, he acquired 4,363 shares of common stock at a value of $2.01 per share, issued in lieu of net salary. Following this stock issuance, Weis directly owns 25,483 shares of Alaunos Therapeutics common stock.
Jerman Michael Allen reported acquisition or exercise transactions in this Form 4 filing.
Alaunos Therapeutics, Inc. reported that director Michael Allen Jerman received a grant of 8,138 shares of common stock on 2026-07-23, valued at $1.92 per share. The shares were issued in lieu of board fees and increase his direct holdings to 23,759 shares.
Alaunos Therapeutics, Inc. CEO Holger Weis received a grant of 4,568 shares of common stock on 2026-07-23 at $1.92 per share, issued in lieu of net salary. After this compensation-related acquisition, he directly holds 21,120 common shares.
Robert W. Postma, a director of Alaunos Therapeutics, Inc., reported the acquisition of 8,463 shares of common stock on 23 July 2026 at $1.92 per share, described as shares issued in lieu of board fees. Following this grant, he holds 58,609 shares directly and additional indirect holdings of 24 shares through his spouse's IRA and 62,416 shares through WaterMill Asset Management Corp.
Vieser Jaime reported acquisition or exercise transactions in this Form 4 filing.
Alaunos Therapeutics, Inc. director Jaime Vieser reported an equity compensation grant of 8,789 shares of common stock on 2026-07-23, valued at $1.92 per share and issued in lieu of board fees. Following this award, he holds 47,642 shares directly. The report also lists indirect holdings of 2,100 shares held by his children and 13,503 shares held by Brushwood LLC, where he serves as Manager.